ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) Can’t Be Less Risky. Short Interest Decreased

May 16, 2018 - By Adrian Erickson

Argos Therapeutics, Inc. (OTCMKTS:ARGS) Logo

Investors sentiment increased to 0.85 in 2017 Q4. Its up 0.22, from 0.63 in 2017Q3. It increased, as 8 investors sold Argos Therapeutics, Inc. shares while 5 reduced holdings. 6 funds opened positions while 5 raised stakes. 2.48 million shares or 6.25% less from 2.64 million shares in 2017Q3 were reported.
Virtu Financial Ltd Com owns 112,208 shares for 0% of their portfolio. Credit Suisse Ag holds 20,074 shares or 0% of its portfolio. Two Sigma Secs Limited Liability has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS) for 47,961 shares. Moreover, Wasatch Inc has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS) for 643,265 shares. Financial Bank Of Mellon invested 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Northern Tru holds 0% or 43,244 shares in its portfolio. State Street Corp reported 11,900 shares. Meeder Asset invested in 22,439 shares or 0% of the stock. Deutsche Fincl Bank Ag has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS). California Pub Employees Retirement Sys invested 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Royal Fincl Bank Of Canada stated it has 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Moreover, Blackrock has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS) for 7,526 shares. Guggenheim Cap Limited Com holds 24,877 shares or 0% of its portfolio. Vanguard Grp Inc reported 1.05 million shares or 0% of all its holdings. Stifel Finance Corp accumulated 66,550 shares.

The stock of ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) registered a decrease of 91.01% in short interest. ARGS’s total short interest was 65,500 shares in May as published by FINRA. Its down 91.01% from 728,400 shares, reported previously.

The stock decreased 9.43% or $0.018 during the last trading session, reaching $0.172. About 67,166 shares traded. Argos Therapeutics, Inc. (OTCMKTS:ARGS) has declined 87.69% since May 16, 2017 and is downtrending. It has underperformed by 99.24% the S&P500.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $1.82 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


WP Twitter Auto Publish Powered By : XYZScripts.com